Sintilimab plus bevacizumab and CapeOx as first-line treatment in RAS-mutant, microsatellite stable, unresectable metastatic colorectal cancer patients: Updated survival results and biomarker analyses of the BBCAPX-II study (ESMO Asia 2026) - Oct 1, 2026 - Abstract #192P; Pres time: Dec 4, 2026; 05:15 PM - 06:15 PM; Location: Poster area (Exhibition); No abstract available
Biomarker • Clinical • Metastases • Colorectal Cancer • Oncology • Solid Tumor • RAS
|
|
Ning Zhu; Zhijun Yuan; Yan Zhang; Dan Li; Chenhan Zhong; Jiekai Yu; Shanshan Weng; Caixia Dong; Hanguang Hu; Yanhua Chen; Yuping Hao; Changbin Zhu; Ying Yuan; Fang Xuefeng
|